@FierceMedDev: St. Louis spinal/sports medicine co. ISTO Technologies names George Dunbar CEO. Release | Follow @FierceMedDev
@MichaelGFierce: Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: How much is that artificial hip? Your doctor probably doesn't know. Story | Follow @EmilyWFierce
@MarkHFierce: Three heavy hitters--Covidien, NEA and Lightstone--are jointly investing in a new Irish med tech company. Release | Follow @MarkHFierce
> Dako said it will work with Merck ($MRK) to develop companion diagnostic tests for potential new cancer drugs in the pipeline. Story
> Wound-care services company Healogics is reportedly exploring a sale that could net close to $1 billion. Story
> Doctors generally have no idea how much basic medical implants actually cost, according to a new study published in the journal Health Affairs. Story
> BioCardia gained a CE mark for a new transendocardial delivery catheter, which is designed to infuse biologic therapies into the heart. Item
> Sequenom ($SQNM) said it has signed a national deal with an unnamed "leading benefits provider" to cover the company's MaterniT21 PLUS prenatal diagnostic test, the second such agreement for the San Diego company. Item
Biotech News
@FierceBiotech: MannKind has an FDA advisory committee review of Afrezza set for April 1. Release | Follow @FierceBiotech
@JohnCFierce: 1 of today's top stories: Ex-$BMS R&D chief Sigal makes the leap into venture finance. Joins Mott at NEA. Story | Follow @JohnCFierce
@DamianFierce: Analyst says Lombard's U.S. IPO could come in at $70M. EP Vantage story | Follow @DamianFierce
@EmilyMFierce: Blast at San Francisco Amgen lab injures 2. Story | Follow @EmilyMFierce
> FDA reviewer flunks Chelsea's effort at a comeback for Northera. Story
> It's an industry tradition: Biopharma gets giddy as JPMorgan gets the party started. Article
> Amgen spinoff Atara cranks its Series B up to $52M. Report
Pharma News
@FiercePharma: Best-read FiercePharma special yesterday: Top 10 Drug Patent Losses of 2014. Report | Follow @FiercePharma
@TracyStaton: Top FiercePharma news Thursday: Wanna trade? Novartis + Merck reportedly negotiating $5B unit swap. Story | Follow @TracyStaton
@EricPFierce: Genentech liquid Tamiflu delays stem from packaging issues. Shortages possible but capsules available. Story from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: With CEO pick, Teva bets turnaround savvy will trump pharma know-how. Thursday's story | Follow @CarlyHFierce
> DOJ wants Aegerion to talk about what it's been saying. Story
> KV gets a second shot at forcing the FDA to restrict compounders on Makena. Article
> Shire not quite to the finish line with ViroPharma. More
> C-suite shuffle: Amgen CFO Peacock resigns. Item